GAMMA Investing LLC increased its stake in shares of AdaptHealth Corp. (NASDAQ:AHCO - Free Report) by 2,883.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,007 shares of the company's stock after buying an additional 78,292 shares during the quarter. GAMMA Investing LLC owned 0.06% of AdaptHealth worth $878,000 at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Rhumbline Advisers lifted its holdings in shares of AdaptHealth by 0.5% during the fourth quarter. Rhumbline Advisers now owns 313,110 shares of the company's stock valued at $2,981,000 after acquiring an additional 1,691 shares during the period. Principal Financial Group Inc. increased its position in shares of AdaptHealth by 204.0% during the 4th quarter. Principal Financial Group Inc. now owns 1,652,765 shares of the company's stock worth $15,735,000 after purchasing an additional 1,109,021 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in AdaptHealth by 25.0% during the 4th quarter. New York State Common Retirement Fund now owns 758,562 shares of the company's stock valued at $7,222,000 after purchasing an additional 151,638 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new position in AdaptHealth in the fourth quarter valued at about $1,000,000. Finally, Bank of New York Mellon Corp grew its stake in AdaptHealth by 1.9% during the fourth quarter. Bank of New York Mellon Corp now owns 759,302 shares of the company's stock worth $7,229,000 after buying an additional 14,378 shares during the last quarter. Institutional investors and hedge funds own 82.67% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the company. Truist Financial decreased their price target on AdaptHealth from $14.00 to $13.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. Royal Bank Of Canada lowered their target price on AdaptHealth from $14.00 to $13.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. Canaccord Genuity Group upped their price target on AdaptHealth from $13.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday, February 26th. Finally, Robert W. Baird raised their price objective on shares of AdaptHealth from $14.00 to $16.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, AdaptHealth currently has an average rating of "Buy" and an average target price of $13.40.
Get Our Latest Stock Report on AdaptHealth
AdaptHealth Stock Down 1.0%
AHCO traded down $0.09 during trading on Friday, reaching $8.40. The company had a trading volume of 921,474 shares, compared to its average volume of 1,446,868. The company has a market cap of $1.13 billion, a P/E ratio of 14.73, a PEG ratio of 0.98 and a beta of 1.64. AdaptHealth Corp. has a 12 month low of $7.11 and a 12 month high of $11.90. The company has a debt-to-equity ratio of 1.25, a current ratio of 1.29 and a quick ratio of 1.07. The business's fifty day moving average price is $8.60 and its 200 day moving average price is $9.48.
AdaptHealth Company Profile
(
Free Report)
AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.
Featured Stories

Before you consider AdaptHealth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AdaptHealth wasn't on the list.
While AdaptHealth currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.